论文部分内容阅读
柳氮磺胺吡啶(SASP),用于治疗肠道炎症性疾病已40多年,临床效果满意。本文拟对其临床疗效、不良反应、药物代谢和低毒新药的研制进展作一综述,以便为临床应用提供参考。 1.SASP治疗活动性溃疡性结肠炎的临床对照试验 60年代初期,用SASP治疗溃疡性结肠炎并以安慰剂做对照试验,每天4g,连续3周,能使65~80%的病人症状缓解,约为对照病人的两倍(P<0.05)。因而确定该药为治疗结肠炎急性发作和恶化的有效药物。Azad Khan等对170例患者随机分为3组,每组不少于50人,每天分别接受1g、2g、4g的剂量,持续6个月;另有10例患者每天
Sulfasalazine (SASP), for the treatment of intestinal inflammatory disease has more than 40 years, the clinical effect is satisfactory. This article intends to review its clinical efficacy, adverse reactions, drug metabolism and development of new drugs with low toxicity in order to provide a reference for clinical application. 1.SASP treatment of active ulcerative colitis clinical control trial In the early 60s, the treatment of ulcerative colitis with SASP and placebo-controlled trials, daily for 3 weeks, 65 to 80% of the patients can ease the symptoms , About double the control patients (P <0.05). Thus determine the drug for the treatment of acute exacerbations and exacerbations of effective drugs. Azad Khan and other 170 patients were randomly divided into three groups of not less than 50 people each received 1g, 2g, 4g dose for 6 months; another 10 patients daily